Correlation Between Xvivo Perfusion and BioArctic

Can any of the company-specific risk be diversified away by investing in both Xvivo Perfusion and BioArctic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xvivo Perfusion and BioArctic into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Xvivo Perfusion AB and BioArctic AB, you can compare the effects of market volatilities on Xvivo Perfusion and BioArctic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xvivo Perfusion with a short position of BioArctic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xvivo Perfusion and BioArctic.

Diversification Opportunities for Xvivo Perfusion and BioArctic

0.0

Correlation Coefficient

Xvivo Perfusion  BioArctic

Pay attention - limited upside

The 3 months correlation between Xvivo and BioArctic is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Xvivo Perfusion AB and BioArctic AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioArctic AB and Xvivo Perfusion is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xvivo Perfusion AB are associated (or correlated) with BioArctic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioArctic AB has no effect on the direction of Xvivo Perfusion i.e., Xvivo Perfusion and BioArctic go up and down completely randomly.

Pair Corralation between Xvivo Perfusion and BioArctic

Assuming the 90 days trading horizon Xvivo Perfusion AB is expected to under-perform the BioArctic. But the stock apears to be less risky and, when comparing its historical volatility, Xvivo Perfusion AB is 2.24 times less risky than BioArctic. The stock trades about -0.05 of its potential returns per unit of risk. The BioArctic AB is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  16,410  in BioArctic AB on September 2, 2024 and sell it today you would earn a total of  2,900  from holding BioArctic AB or generate 17.67% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Xvivo Perfusion AB  vs.  BioArctic AB

Xvivo Perfusion AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Xvivo Perfusion AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

BioArctic AB

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in BioArctic AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, BioArctic sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Xvivo Perfusion and BioArctic

The main advantage of trading using opposite Xvivo Perfusion and BioArctic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xvivo Perfusion position performs unexpectedly, BioArctic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioArctic will offset losses from the drop in BioArctic's long position.

The idea behind Xvivo Perfusion AB and BioArctic AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.